JPWO2019212899A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019212899A5 JPWO2019212899A5 JP2020560463A JP2020560463A JPWO2019212899A5 JP WO2019212899 A5 JPWO2019212899 A5 JP WO2019212899A5 JP 2020560463 A JP2020560463 A JP 2020560463A JP 2020560463 A JP2020560463 A JP 2020560463A JP WO2019212899 A5 JPWO2019212899 A5 JP WO2019212899A5
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- inhibitor
- subject
- polymorphism
- nucleobase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002401 inhibitory effect Effects 0.000 claims 26
- 108010017987 CD30 Ligand Proteins 0.000 claims 25
- 102100003083 TNFSF8 Human genes 0.000 claims 25
- 239000003112 inhibitor Substances 0.000 claims 23
- 102100002239 TNFSF15 Human genes 0.000 claims 6
- 101710022241 TNFSF15 Proteins 0.000 claims 6
- 206010011401 Crohn's disease Diseases 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 3
- 102100009538 TNFRSF8 Human genes 0.000 claims 2
- 101710040533 TNFRSF8 Proteins 0.000 claims 2
- 102000003842 Tumor Necrosis Factor Ligand Superfamily Member 15 Human genes 0.000 claims 2
- 108090000138 Tumor Necrosis Factor Ligand Superfamily Member 15 Proteins 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003176 fibrotic Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 Thalidomide Drugs 0.000 claims 1
- 108010077389 Ustekinumab Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002068 genetic Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 200000000009 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664720P | 2018-04-30 | 2018-04-30 | |
| US62/664,720 | 2018-04-30 | ||
| US201862681557P | 2018-06-06 | 2018-06-06 | |
| US62/681,557 | 2018-06-06 | ||
| US201862784179P | 2018-12-21 | 2018-12-21 | |
| US62/784,179 | 2018-12-21 | ||
| PCT/US2019/029402 WO2019212899A1 (fr) | 2018-04-30 | 2019-04-26 | Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021532060A JP2021532060A (ja) | 2021-11-25 |
| JPWO2019212899A5 true JPWO2019212899A5 (fr) | 2022-05-09 |
Family
ID=68386125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560463A Pending JP2021532060A (ja) | 2018-04-30 | 2019-04-26 | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20210238684A1 (fr) |
| EP (2) | EP3774897B1 (fr) |
| JP (1) | JP2021532060A (fr) |
| KR (1) | KR20210013062A (fr) |
| CN (1) | CN112368301A (fr) |
| AU (1) | AU2019261933A1 (fr) |
| CA (1) | CA3098720A1 (fr) |
| DK (1) | DK3774897T3 (fr) |
| ES (1) | ES2962715T3 (fr) |
| FI (1) | FI3774897T3 (fr) |
| HR (1) | HRP20231367T1 (fr) |
| HU (1) | HUE063908T2 (fr) |
| LT (1) | LT3774897T (fr) |
| MA (1) | MA52251A (fr) |
| MD (1) | MD3774897T2 (fr) |
| PL (1) | PL3774897T3 (fr) |
| PT (1) | PT3774897T (fr) |
| RS (1) | RS64747B1 (fr) |
| SI (1) | SI3774897T1 (fr) |
| TW (1) | TW202003573A (fr) |
| WO (1) | WO2019212899A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230157356A (ko) | 2021-02-17 | 2023-11-16 | 프로메테우스 바이오사이언시즈, 인크. | 항-cd30l 항체 및 이의 용도 |
| WO2024026386A1 (fr) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | Formulations d'anticorps anti-tl1a |
| WO2024026395A1 (fr) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| DE3684446D1 (de) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | Arzneimittel mit verzoegerter stossweiser freisetzung. |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| WO2008106451A2 (fr) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Procédés d'utilisation de polymorphismes nucléotidiques uniques dans le gène tl1a pour prédire ou diagnostiquer une affection intestinale inflammatoire |
| US20120225427A1 (en) * | 2009-08-21 | 2012-09-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | sPLA2 IIA Polymorphism Analysis for the Diagnosis/Prognosis of a Cardiovascular Disease/Event |
| EP2841456B1 (fr) * | 2012-04-27 | 2018-06-13 | Novo Nordisk A/S | Protéines de liaison au ligand de cd30 humaine |
| CA2875681A1 (fr) * | 2012-06-04 | 2013-12-12 | Gaurav Agrawal | Compositions et procedes de traitement de la maladie de crohn et des pathologies et infections associees |
| US10322174B2 (en) * | 2016-10-26 | 2019-06-18 | Cedars-Sinai Medical Center | Neutralizing anti-TL1A monoclonal antibodies |
-
2019
- 2019-04-26 EP EP19796203.8A patent/EP3774897B1/fr active Active
- 2019-04-26 PT PT197962038T patent/PT3774897T/pt unknown
- 2019-04-26 HR HRP20231367TT patent/HRP20231367T1/hr unknown
- 2019-04-26 JP JP2020560463A patent/JP2021532060A/ja active Pending
- 2019-04-26 AU AU2019261933A patent/AU2019261933A1/en active Pending
- 2019-04-26 US US17/051,731 patent/US20210238684A1/en active Pending
- 2019-04-26 PL PL19796203.8T patent/PL3774897T3/pl unknown
- 2019-04-26 ES ES19796203T patent/ES2962715T3/es active Active
- 2019-04-26 MA MA052251A patent/MA52251A/fr unknown
- 2019-04-26 LT LTEPPCT/US2019/029402T patent/LT3774897T/lt unknown
- 2019-04-26 KR KR1020207033851A patent/KR20210013062A/ko not_active Application Discontinuation
- 2019-04-26 CN CN201980044299.1A patent/CN112368301A/zh active Pending
- 2019-04-26 WO PCT/US2019/029402 patent/WO2019212899A1/fr active Application Filing
- 2019-04-26 EP EP23192639.5A patent/EP4296285A3/fr active Pending
- 2019-04-26 FI FIEP19796203.8T patent/FI3774897T3/fi active
- 2019-04-26 CA CA3098720A patent/CA3098720A1/fr active Pending
- 2019-04-26 HU HUE19796203A patent/HUE063908T2/hu unknown
- 2019-04-26 DK DK19796203.8T patent/DK3774897T3/da active
- 2019-04-26 RS RS20231000A patent/RS64747B1/sr unknown
- 2019-04-26 SI SI201930656T patent/SI3774897T1/sl unknown
- 2019-04-26 MD MDE20210158T patent/MD3774897T2/ro unknown
- 2019-04-30 TW TW108115107A patent/TW202003573A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clarke et al. | New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression | |
| Bogaert et al. | Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease | |
| JP2018203727A (ja) | 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤 | |
| US20070082347A1 (en) | Gene variants and use thereof | |
| KR101566064B1 (ko) | 연령-관련 황반 변성에서의 유전자 다형성 | |
| CA2544708A1 (fr) | Biomarqueurs du cancer du foie | |
| EP3218515A1 (fr) | Méthodes thérapeutiques et diagnostiques pour les troubles à médiation par l'il-33 | |
| JP2010522555A (ja) | 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのｃｈｒ２およびｃｈｒ１６の遺伝的変異 | |
| JP2009539960A (ja) | 加齢黄斑変性に対する保護および処置 | |
| Bridges Jr et al. | Single‐nucleotide polymorphisms in tumor necrosis factor receptor genes: definition of novel haplotypes and racial/ethnic differences | |
| EP3207136A1 (fr) | Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7 | |
| CN114381512A (zh) | 预测对hdl升高剂或hdl模拟剂疗法的应答性的遗传标记 | |
| FI3774897T3 (fi) | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon | |
| JP6687532B2 (ja) | 神経変性疾患のミトコンドリアマーカー | |
| KR20180109811A (ko) | 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물 | |
| WO2016042114A1 (fr) | Cxcl14 en tant que biomarqueur de l'activité de la voie hedgehog pour diagnostic, le pronostic et le traitement d'une fibrose pulmonaire idiopathique | |
| JPWO2019212899A5 (fr) | ||
| Pauciullo et al. | Wingless‐type MMTV integration site family member 2 (WNT 2) gene is associated with resistance to MAP in faecal culture and antibody response in Holstein cattle | |
| JP2021501598A (ja) | 免疫療法に対する悪性疾患の応答性を決定するための方法 | |
| EP3126521A1 (fr) | Gène de fusion de hnf4g-rspo2 et utilisation de celui-ci dans le traitement du cancer | |
| Lee et al. | Association of endothelin-1 gene polymorphisms with variant angina in Korean patients | |
| US20080268453A1 (en) | Types of lymphoma and method for prognosis thereof | |
| JP2021502977A5 (fr) | ||
| EP1536000A1 (fr) | Procede permettant d'evaluer une maladie inflammatoire | |
| KR102060896B1 (ko) | 항-tnf 제제에 대한 반응성 예측용 단일염기다형성 마커 조성물 및 이를 이용한 항-tnf 제제에 대한 반응성 예측 방법 |